Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluation of the Effectiveness of Psychological First Aid Training for Community Nurses in China: A Quasi-Experimental Study on Knowledge and Skills Enhancement.

Nursing open·2026

Same author

Fotemustine-containing chemotherapy suggests lower toxicity with comparable efficacy versus high-dose methotrexate-based regimens: a retrospective cohort analysis.

Therapeutic advances in medical oncology·2026

Same author

Identification and characterization of MARCO-expressing tumor-associated macrophages in pancreatic ductal adenocarcinoma with pan-cancer relevance.

NPJ precision oncology·2026

Same author

A first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma.

Cancer·2026

Same author

Outcomes and prognostic factors of alternative treatment regimens for angioimmunoblastic T-cell lymphoma: a retrospective analysis.

Frontiers in oncology·2025

Same author

Grammatical error correction for low-resource languages: a review of challenges, strategies, computational and future directions.

PeerJ. Computer science·2025

Search research articles

Related Experiment Video

Updated: Jul 26, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma.

Xiaoshuang Kong¹, Xudong Zhang¹, Mengjie Ding¹

¹Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Cancer Medicine

|January 25, 2023

Summary

Decitabine combined with RDHAP shows promise for relapsed/refractory diffuse large B-cell lymphoma (R/R-DLBCL), improving duration of remission without increasing toxicity. This combination therapy offers a potential new treatment option for R/R-DLBCL patients.

Keywords:

chemotherapy decitabine diffuse large B-cell lymphoma

More Related Videos

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

Related Experiment Videos

Last Updated: Jul 26, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

Area of Science:

Hematology
Oncology
Clinical Trials

Background:

Relapsed/refractory diffuse large B-cell lymphoma (R/R-DLBCL) presents a significant unmet medical need.
Effective salvage therapies are crucial for improving outcomes in R/R-DLBCL patients.

Purpose of the Study:

To evaluate the efficacy and safety of decitabine in combination with rituximab, cisplatin, cytarabine, and dexamethasone (decitabine-RDHAP) for R/R-DLBCL.
To compare the decitabine-RDHAP regimen against the standard RDHAP regimen in R/R-DLBCL patients.

Main Methods:

A clinical trial involving 56 patients with R/R-DLBCL, divided into decitabine-RDHAP (n=35) and RDHAP (n=21) groups.
Primary endpoints included overall response rate (ORR) and duration of remission (DOR).
Secondary endpoints assessed toxicity, progression-free survival (PFS), and overall survival (OS).

Main Results:

The ORR was similar between groups (40% for decitabine-RDHAP vs. 33% for RDHAP).
The decitabine-RDHAP regimen demonstrated a significantly longer duration of remission (p=0.044).
Median PFS and OS were numerically higher in the decitabine-RDHAP group, with no significant differences in adverse events between groups.

Conclusions:

The decitabine-RDHAP regimen is an effective and well-tolerated treatment option for R/R-DLBCL.
This combination therapy represents a promising salvage regimen for patients with R/R-DLBCL.
Further investigation into decitabine-RDHAP for R/R-DLBCL is warranted.